FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2016592541> ?p ?o ?g. }

• W2016592541 endingPage "122" @default.
• W2016592541 startingPage "115" @default.
• W2016592541 abstract "Amyotrophic lateral sclerosis (ALS) is a rapidly progressing neurodegenerative disease in which the majority of upper and lower motor neurons are degenerated. Despite intensive efforts to identify drug targets and develop neuroprotective strategies, effective therapeutics for ALS remains unavailable. The identification and characterization of novel targets and pathways remain crucial in the development of ALS therapeutics. Adenosine is a major neuromodulator that actively regulates synaptic transmission. Interestingly, adenosine levels are significantly elevated in the cerebrospinal fluid (CSF) of progressing human ALS patients. In the current study, we showed that adenosine 2a receptor (A2aR), but not adenosine 1 receptor (A1R), is highly enriched in spinal (motor) neurons. A2aR expression is also selectively increased at the symptomatic onset in the spinal cords of SOD1G93A mice and end-stage human ALS spinal cords. Interestingly, we found that direct adenosine treatment is sufficient to induce embryonic stem cell-derived motor neuron (ESMN) cell death in cultures. Subsequent pharmacological inhibition and partial genetic ablation of A2aR (A2aR+/−) significantly protect ESMN from SOD1G93A+ astrocyte-induced cell death and delay disease progression of SOD1G93A mice. Taken together, our results provide compelling novel evidence that A2aR-mediated adenosine signaling contributes to the selective spinal motor neuron degeneration observed in the SOD1G93A mouse model of ALS." @default.
• W2016592541 created "2016-06-24" @default.
• W2016592541 creator A5012893954 @default.
• W2016592541 creator A5021443644 @default.
• W2016592541 creator A5037033529 @default.
• W2016592541 creator A5057085180 @default.
• W2016592541 date "2015-05-01" @default.
• W2016592541 modified "2023-10-17" @default.
• W2016592541 title "Suppression of adenosine 2a receptor (A2aR)-mediated adenosine signaling improves disease phenotypes in a mouse model of amyotrophic lateral sclerosis" @default.
• W2016592541 cites W1511707795 @default.
• W2016592541 cites W1521659744 @default.
• W2016592541 cites W1551550807 @default.
• W2016592541 cites W1605590717 @default.
• W2016592541 cites W1844553425 @default.
• W2016592541 cites W1964999601 @default.
• W2016592541 cites W1968599797 @default.
• W2016592541 cites W1981149039 @default.
• W2016592541 cites W1981577144 @default.
• W2016592541 cites W1982734210 @default.
• W2016592541 cites W1991323513 @default.
• W2016592541 cites W1991379835 @default.
• W2016592541 cites W1996024251 @default.
• W2016592541 cites W2003618511 @default.
• W2016592541 cites W2006536013 @default.
• W2016592541 cites W2007990537 @default.
• W2016592541 cites W2013135033 @default.
• W2016592541 cites W2028684902 @default.
• W2016592541 cites W2033158384 @default.
• W2016592541 cites W2056849709 @default.
• W2016592541 cites W2058666690 @default.
• W2016592541 cites W2066828509 @default.
• W2016592541 cites W2068147651 @default.
• W2016592541 cites W2073864172 @default.
• W2016592541 cites W2093480131 @default.
• W2016592541 cites W2094384373 @default.
• W2016592541 cites W2096386031 @default.
• W2016592541 cites W2107768418 @default.
• W2016592541 cites W2115155255 @default.
• W2016592541 cites W2120144854 @default.
• W2016592541 cites W2123370994 @default.
• W2016592541 cites W2124940469 @default.
• W2016592541 cites W2135027010 @default.
• W2016592541 cites W2135522980 @default.
• W2016592541 cites W2137731628 @default.
• W2016592541 cites W2142638433 @default.
• W2016592541 cites W2146546145 @default.
• W2016592541 cites W2147270524 @default.
• W2016592541 cites W2150523249 @default.
• W2016592541 cites W2154945114 @default.
• W2016592541 cites W2156482156 @default.
• W2016592541 cites W2160035187 @default.
• W2016592541 cites W2166043619 @default.
• W2016592541 cites W2166206888 @default.
• W2016592541 cites W2170271315 @default.
• W2016592541 cites W2581259096 @default.
• W2016592541 cites W4322696962 @default.
• W2016592541 doi "https://doi.org/10.1016/j.expneurol.2015.03.004" @default.
• W2016592541 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5363273" @default.
• W2016592541 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25779930" @default.
• W2016592541 hasPublicationYear "2015" @default.
• W2016592541 type Work @default.
• W2016592541 sameAs 2016592541 @default.
• W2016592541 citedByCount "41" @default.
• W2016592541 countsByYear W20165925412015 @default.
• W2016592541 countsByYear W20165925412016 @default.
• W2016592541 countsByYear W20165925412017 @default.
• W2016592541 countsByYear W20165925412018 @default.
• W2016592541 countsByYear W20165925412019 @default.
• W2016592541 countsByYear W20165925412020 @default.
• W2016592541 countsByYear W20165925412021 @default.
• W2016592541 countsByYear W20165925412022 @default.
• W2016592541 countsByYear W20165925412023 @default.
• W2016592541 crossrefType "journal-article" @default.
• W2016592541 hasAuthorship W2016592541A5012893954 @default.
• W2016592541 hasAuthorship W2016592541A5021443644 @default.
• W2016592541 hasAuthorship W2016592541A5037033529 @default.
• W2016592541 hasAuthorship W2016592541A5057085180 @default.
• W2016592541 hasBestOaLocation W20165925412 @default.
• W2016592541 hasConcept C126322002 @default.
• W2016592541 hasConcept C169760540 @default.
• W2016592541 hasConcept C170493617 @default.
• W2016592541 hasConcept C25498285 @default.
• W2016592541 hasConcept C2776752467 @default.
• W2016592541 hasConcept C2776991684 @default.
• W2016592541 hasConcept C2777542381 @default.
• W2016592541 hasConcept C2778491162 @default.
• W2016592541 hasConcept C2778938600 @default.
• W2016592541 hasConcept C2779134260 @default.
• W2016592541 hasConcept C2780596555 @default.
• W2016592541 hasConcept C2780775167 @default.
• W2016592541 hasConcept C529278444 @default.
• W2016592541 hasConcept C67907053 @default.
• W2016592541 hasConcept C71924100 @default.
• W2016592541 hasConcept C86803240 @default.
• W2016592541 hasConceptScore W2016592541C126322002 @default.
• W2016592541 hasConceptScore W2016592541C169760540 @default.
• W2016592541 hasConceptScore W2016592541C170493617 @default.
• W2016592541 hasConceptScore W2016592541C25498285 @default.

• next